About Evrysdi Evrysdi is an SMN2-splicing modifier designed to increase functional SMN protein production. With the introduction of a new tablet formulation, Evrysdi now offers an alternative ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, which is in a pair of late-stage studies in lupus.

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Biogen shares fell, after the biotechnology company forecast lower-than-expected revenue and profit for this year, saying multiple-sclerosis drug sales will decline further and will only be partially ...

American biotechnology company Biogen (BIIB) expects lower profits in 2025, impacted by a stronger dollar (DX=F, DX-Y.NYB) ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech ...

Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company ...

A U.S. judge ordered federal agencies to restore access to health-related webpages and datasets removed by the Trump ...